Entrada Therapeutics plans sale of 331K shares

Entrada Therapeutics, Inc. filed an amended Form 144 indicating a planned resale of 331,156 shares of common stock.

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. filed an amended Form 144 indicating a planned resale of 331,156 shares of common stock. The shares were originally acquired on October 12, 2016 for cash in connection with a venture financing investment. The common stock is listed on Nasdaq.

Key Figures

Shares to be sold: 331,156 shares of common stock Acquisition date: 10/12/2016 Listing venue: Nasdaq

3 metrics

Shares to be sold 331,156 shares of common stock Identified in the Securities To Be Sold section

Acquisition date 10/12/2016 Date the common stock was acquired in a venture financing investment

Listing venue Nasdaq Common stock listed on Nasdaq as stated in the securities information

Key Terms

Securities To Be Sold, venture financing investment, Nasdaq

3 terms

Securities To Be Sold regulatory

"144/A: Securities To Be Sold Common Stock | 10/12/2016 | Venture Financing Investment"

venture financing investment financial

"Common Stock | 10/12/2016 | Venture Financing Investment | Entrada Therapeutics, Inc."

Nasdaq financial

"07/30/2026 | Nasdaq Common Stock | JonesTrading 555 St. Charles Drive"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Entrada Therapeutics (TRDA) disclose in this Form 144/A?

Entrada Therapeutics discloses a planned resale of 331,156 shares of common stock under an amended Form 144. These shares were acquired for cash in a venture financing investment on October 12, 2016 and are listed on Nasdaq.

How many Entrada Therapeutics (TRDA) shares are covered by this Form 144/A?

The amended Form 144 covers 331,156 shares of common stock. These shares are identified in the “Securities To Be Sold” section and relate to stock acquired for cash through a venture financing investment on October 12, 2016.

When were the Entrada Therapeutics (TRDA) shares planned for sale originally acquired?

The shares planned for sale were originally acquired on October 12, 2016. The filing describes the acquisition as a venture financing investment made for cash, and the same date appears as both the acquisition and consideration date.

What type of security is being sold for Entrada Therapeutics (TRDA) in this Form 144/A?

The security identified is common stock of Entrada Therapeutics, Inc. The filing notes that this common stock is listed on Nasdaq and that 331,156 shares are included in the “Securities To Be Sold” section of the amended Form 144.

Is Entrada Therapeutics (TRDA) issuing new shares in this Form 144/A filing?

No, the Form 144/A relates to a resale of existing common stock, not a new share issuance. The document describes 331,156 previously acquired shares being registered for potential sale, tied to a past venture financing investment made for cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 07:50 PM Accepted by SEC EDGAR 08/10/2026 - 07:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001674324
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001674324-26-000006
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	ENTRADA THERAPEUTICS, INC.
SEC File Number	001-40969
Address of Issuer	ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MASSACHUSETTS 02210
Phone	(857) 520-9158
Name of Person for Whose Account the Securities are To Be Sold	5AM Ventures V, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliated stockholder

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	165578	1084536	38820616	07/30/2026	Nasdaq
Common Stock	JonesTrading 555 St. Charles Drive, Suite 200 Thousand Oaks CA 91360	165578	1084536	38820616	07/30/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/12/2016	Venture Financing Investment	Entrada Therapeutics, Inc.			331156	10/12/2016	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks
Date of Notice	08/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Andrew J. Schwab
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)